Arcadia Biosciences, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Arcadia Biosciences reported a net income from continuing operations for Q3 2025, but a significant credit loss and declining cash reserves raise substantial doubt about its ability to continue as a going concern.
NASDAQ
Arcadia Biosciences reported a significant net loss and substantial doubt about its ability to continue as a going concern, despite increased Zola coconut water sales.
NASDAQ
Arcadia Biosciences reports a net income of $2.6 million for Q1 2025, driven by increased Zola coconut water sales and strategic asset sales, while expressing concerns about its ability to continue as a going concern.
NASDAQ
10-Q: Arcadia Biosciences Reports Third Quarter 2024 Results, Focuses on Zola and Strategic Opportunities
Arcadia Biosciences reported its third quarter 2024 financial results, highlighting the sale of its GoodWheat brand and a focus on its Zola coconut water business.
NASDAQ
Arcadia Biosciences reports a net income of $1.1 million for Q2 2024, driven by strategic asset sales and reduced operating expenses, while also noting concerns about its ability to continue as a going concern.
NASDAQ
Arcadia Biosciences reported a net loss of $2.4 million for the first quarter of 2024 and expressed substantial doubt about its ability to continue as a going concern.